|Number of samples:||94|
|Release date:||Oct 16 2018|
|Last update date:||Nov 20 2018|
|Diseases:||Kidney Diseases, Kidney Diseases, Cystic|
|Dataset link||Evaluation of APOL1 ASO in a novel model of APOL1-associated renal disease|
APOL1 G0 and G1 transgenic mice were dosed with PBS (vehicle), 50 mg/kg control ASO (non-targeting ASO of the same chemistry as targeting ASO) or 50 mg/kg APOL1 ASO once/week for 4 weeks. One day after the last ASO dose, cohorts were divided and half were challenged with PBS and half were challenged with IFNgamma. Kidney and Liver tissues were harvested 48 hours after challenge for analysis. N=3-4 per group.